Principal Financial Group Inc. raised its holdings in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) by 6.0% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 586,141 shares of the biotechnology company’s stock after acquiring an additional 33,273 shares during the quarter. Principal Financial Group Inc. owned approximately 0.75% of Spectrum Pharmaceuticals worth $8,247,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Prudential Financial Inc. lifted its holdings in shares of Spectrum Pharmaceuticals by 7.5% in the 3rd quarter. Prudential Financial Inc. now owns 125,141 shares of the biotechnology company’s stock worth $1,761,000 after buying an additional 8,745 shares during the period. New York State Teachers Retirement System lifted its holdings in shares of Spectrum Pharmaceuticals by 4.6% in the 3rd quarter. New York State Teachers Retirement System now owns 88,795 shares of the biotechnology company’s stock worth $1,249,000 after buying an additional 3,900 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in shares of Spectrum Pharmaceuticals in the 3rd quarter worth $212,000. First Quadrant L P CA purchased a new stake in shares of Spectrum Pharmaceuticals in the 3rd quarter worth $235,000. Finally, Fisher Asset Management LLC purchased a new stake in shares of Spectrum Pharmaceuticals in the 3rd quarter worth $2,521,000. 71.88% of the stock is currently owned by institutional investors.

Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) opened at $18.62 on Thursday. The company has a current ratio of 5.04, a quick ratio of 4.89 and a debt-to-equity ratio of 0.33. Spectrum Pharmaceuticals, Inc. has a 12 month low of $3.88 and a 12 month high of $21.95.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06). The company had revenue of $36.40 million for the quarter, compared to analysts’ expectations of $33.27 million. Spectrum Pharmaceuticals had a negative return on equity of 29.73% and a negative net margin of 58.94%. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.07) earnings per share. research analysts anticipate that Spectrum Pharmaceuticals, Inc. will post -1.03 earnings per share for the current fiscal year.

Several brokerages have weighed in on SPPI. HC Wainwright reiterated a “buy” rating on shares of Spectrum Pharmaceuticals in a report on Friday, November 3rd. Guggenheim began coverage on Spectrum Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $32.00 target price for the company. Jefferies Group upped their target price on Spectrum Pharmaceuticals to $25.00 and gave the stock a “buy” rating in a report on Friday, October 20th. Zacks Investment Research cut Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Finally, ValuEngine upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Spectrum Pharmaceuticals has a consensus rating of “Buy” and an average price target of $21.40.

COPYRIGHT VIOLATION NOTICE: “Spectrum Pharmaceuticals, Inc. (SPPI) Shares Bought by Principal Financial Group Inc.” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/spectrum-pharmaceuticals-inc-sppi-shares-bought-by-principal-financial-group-inc/1749340.html.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Want to see what other hedge funds are holding SPPI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).

Institutional Ownership by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.